درباره این اپیزود
Welcome to the second part of our Cancer Cachexia ASCO 2025 Highlights. Cancer cachexia is a progressive muscle-wasting syndrome that significantly diminishes the quality of life for many patients with cancer. For the second installment we are joined by Professor Jeffrey Crawford who will be sharing his highlights from ASCO 2025, specifically looking at key highlights on emerging therapeutic agents for cancer cachexia including the hypothesis guiding drug development, pioneering clinical trials, and their results.
This discussion was originally broadcast as a Conference Highlights Video, published as part of the American Cancer Society - Cancer Cachexia Knowledge Hub educational program. To view the original video please visit https://cancercachexia.knowledgehub.wiley.com/conference-coverage/asco-2025-highlights/. The Knowledge Hub also contains additional educational materials on cancer cachexia, including two ACCME accredited webinar broadcasts, conference highlights from AACR 2025, ASCO 2025, ASCO GI 2026, ESMO 2025, SCWD 2024 and 2025 as well as additional resources such as research article collections and downloadable infographics.
The Cancer Cachexia Knowledge Hub program is supported by an educational grant from Pfizer.
Speaker – Professor Jeffrey Crawford. George Barth Galler Professor for Research in Cancer, Department of Medicine, Duke University Medical Center. Full speaker biography - https://cancercachexia.knowledgehub.wiley.com/faculty/
For more medical education from Wiley, please visit https://focus.wiley.com/
